{
    "id": 23480,
    "fullName": "ALK negative",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "ALK negative indicates a lack of the ALK gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 238,
        "geneSymbol": "ALK",
        "terms": [
            "ALK",
            "CD246",
            "NBLST3"
        ]
    },
    "variant": "negative",
    "createDate": "06/22/2016",
    "updateDate": "09/06/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12806,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CEP-28122 did not inhibit tumor growth in cell line xenograft models of ALK-negative colon carcinoma (PMID: 22203728).",
            "molecularProfile": {
                "id": 24175,
                "profileName": "ALK negative"
            },
            "therapy": {
                "id": 2519,
                "therapyName": "CEP-28122",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2441,
                    "pubMedId": 22203728,
                    "title": "CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22203728"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12802,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALK negative non-small cell lung carcinoma cells were resistant to CEP-28122 in culture and in cell line xenograft models (PMID: 22203728).",
            "molecularProfile": {
                "id": 24175,
                "profileName": "ALK negative"
            },
            "therapy": {
                "id": 2519,
                "therapyName": "CEP-28122",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2441,
                    "pubMedId": 22203728,
                    "title": "CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22203728"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16916,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SGN-35), Adcetris (brentuximab vedotin) treatment resulted in complete remission in 57% (33/58), partial remission in 29% (17/58) of patients with relapsed or refractory systemic anaplastic large cell lymphoma, 72% (42/58) of the patients were ALK-negative (PMID: 22614995; NCT00866047).",
            "molecularProfile": {
                "id": 24175,
                "profileName": "ALK negative"
            },
            "therapy": {
                "id": 2486,
                "therapyName": "Brentuximab vedotin",
                "synonyms": null
            },
            "indication": {
                "id": 50744,
                "name": "anaplastic large cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10385,
                    "pubMedId": 22614995,
                    "title": "Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22614995"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12804,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CEP-28122 did not inhibit growth of ALK-negative leukemia cells in culture (PMID: 22203728).",
            "molecularProfile": {
                "id": 24175,
                "profileName": "ALK negative"
            },
            "therapy": {
                "id": 2519,
                "therapyName": "CEP-28122",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2441,
                    "pubMedId": 22203728,
                    "title": "CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22203728"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12805,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CEP-28122 did not inhibit growth of ALK-negative lymphoma cells in culture (PMID: 22203728).",
            "molecularProfile": {
                "id": 24175,
                "profileName": "ALK negative"
            },
            "therapy": {
                "id": 2519,
                "therapyName": "CEP-28122",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2441,
                    "pubMedId": 22203728,
                    "title": "CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22203728"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18995,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "The presence of DUSP22 rearrangement is associated with a favorable prognosis in patients with ALK-negative anaplastic large cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 33801,
                "profileName": "ALK neg DUSP22 rearrange"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50744,
                "name": "anaplastic large cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18999,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "DUSP22-IRF4 fusion aids in the diagnosis of ALK-negative anaplastic large cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 33803,
                "profileName": "DUSP22 - IRF4 ALK neg"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50744,
                "name": "anaplastic large cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18998,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "TP63 rearrangement aids in the diagnosis of ALK-negative anaplastic large cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 33805,
                "profileName": "ALK neg TP63 rearrange"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50744,
                "name": "anaplastic large cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6993,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Xalkori (crizotinib) treatment resulted in an objective response rate of 69% (89/129), and a median duration of treatment of 7.8 months in ALK negative, ROS1 rearranged non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9022); NCT01945021).",
            "molecularProfile": {
                "id": 34394,
                "profileName": "ALK negative ROS1 rearrange"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6003,
                    "pubMedId": null,
                    "title": "Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).",
                    "url": "http://meetinglibrary.asco.org/content/168126-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24174,
            "profileName": "ALK neg ROS1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24175,
            "profileName": "ALK negative",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33801,
            "profileName": "ALK neg DUSP22 rearrange",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33803,
            "profileName": "DUSP22 - IRF4 ALK neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33805,
            "profileName": "ALK neg TP63 rearrange",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34394,
            "profileName": "ALK negative ROS1 rearrange",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}